ESGO Gyn Oncologist at Fondazione Policlinico Universitario A. Gemelli, IRCCS @unicatt.

Joined May 2011
7 Photos and videos
What a family!! 😍
17 Dec 2025
And that's a wrap!!! The last #IJGCClub of the year, with an incredible guest. 🔥 Thank you, Luis @lchiv4 for such a wonderful and insightful discussion. We had 82 attendees, one of our largest attendances for journal clubs! 🤩 Thanks to @IGCSociety and @ESGO_society for all the support, and to the best fellows for your wonderful questions. You can find the recording here 👉 bit.ly/4rZhL3x @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul
1
5
215
Matteo Loverro retweeted
11 Dec 2025
10
22
945
Matteo Loverro retweeted
8 Dec 2025
#WinterPodcast ❄️ We’re bringing back our most-played episodes—starting with the ESGO/INCIP 2025 Cancer in Pregnancy Guidelines featuring Frédéric Amant 🎧 bit.ly/3MpTa7Q @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul
6
14
777
Matteo Loverro retweeted
1 Dec 2025
3
11
21
2,289
Can’t miss this!! Join us tomorrow!! @IJGConline @IJGCfellows
23 Oct 2025
ℹ️ Join ENYGO next week for a Surgical Mentorship webinar on pelvic exenteration & reconstruction! This series of webinars enables young surgeons to share their accomplishments and discuss them with leading experts. 🙌 On October 30, we welcome: Experts 🔸Gwenael Ferron 🔸Vito Chiantera 🔸Nicolo Bizzarri Presenters 🔸Matteo Loverro 🔸Giuseppe Cucinella 🔸Martina Angeles Moderators 🔸Louisa Proppe 🔸Enrique Chacon
2
6
529
Matteo Loverro retweeted
Super @ESGEorg Congress in Istanbul! Congratulations to the organizing cmt and thanks for inviting me as speaker🤩! @ESGO_society @ENYGO_officia
2
10
379
Matteo Loverro retweeted
17 Oct 2025
A fun and highly interactive #IJGCclub today with Mario Leitao @leitaomd and Giuseppe Cucinella @Cucinella_G!🔥 🔥 Thanks to all who joined, asked questions, and made this session so dynamic. We can’t wait to see you at the next one! 💬✨ Special thank to @ESGO_society @IGCSociety 🫶 @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul
3
13
586
Join us for an outstanding #JournalClub with @Cucinella_G and @leitaomd discussing the best evidences we’ll see for years on this rare condition. @IJGConline @IJGCfellows
11 Oct 2025
Join us #IJGCclub 📆16/10/2025 ⏰11am CDT/6pm CET Mark your calendars 📅 for an exciting #IJGCclub 💥 Endometrial carcinosarcoma without myoinvasion with Giuseppe Cucinella @Cucinella_G and Mario Leitao @leitaomd 💻 bit.ly/4jfSMEP @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul
3
8
521
Matteo Loverro retweeted
1 Oct 2025
📺 Did you miss the last #IJGCclub? Catch up now on our YouTube channel! 🎥 This session covers the ESGO/INCIP guidelines on managing patients with #gynecologicalcancers during pregnancy🤰💜 🔗 Watch here: bit.ly/46LQFTY @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul
5
14
1,269
Matteo Loverro retweeted
23 Sep 2025
2
9
1,055
Matteo Loverro retweeted
Consultations with gynecologic oncologists are important to learn about screening and prevention of gynecologic cancers! @ESGO_society @IJGConline @IGCSociety @WorldGOday @ENYGO_official @IJGCfellows
“Support World GO Day!” ENYGO Past President Nicolo Bizzarri is—will you? 😎🥳 Join him in raising awareness about the importance of screening & prevention of gyne cancers! 💜 #WorldGoDay2025 @NicoloBizzarri @ENYGO_official @EngageEsgo
4
13
806
Matteo Loverro retweeted
19 Sep 2025
#EditorialFellows We are pleased to welcome Matteo Loverro @MatteoLoverro, #GynOnc at the Fondazione Policlinico Universitario A. Gemelli, in Rome 🇮🇹 ✨ Welcome, Matteo! We’re really looking forward to working with you. @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @CSabiniMD @ZaniruRaul
5
13
1,310
A truly thought-provoking review, inspiring reflections on gaps in preoperative diagnosis and surgical management, and even more on future medical therapies. Amazing paper @GiorgioBogani @gcarusomd @leitaomd
1
7
855
MIS works even in non-epithelial OC recurrences… and this impressive series on granulosa cell tumor recurrence is just outstanding. Absolutely unmissable! 🚀🎙️
2
6
666
Matteo Loverro retweeted
🦠 HPV is one of the most common infections worldwide. Evidence shows that vaccination and screening are the most effective tools to prevent disease and reduce stigma. #GOAgainstStigma @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul @WorldGOday
13 Sep 2025
#CervicalCancer is NOT your fault! 💜 ✔️ #HPV infection is very common among sexually active people ✔️ Vaccination is key for primary prevention ⚠️ False beliefs linking HPV to promiscuity fuel vaccine hesitancy for girls ⚠️ Shame and stigma around screening stop women from getting tested Let’s end the shame. Let’s break the stigma. #GOAgainstStigma @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul @WorldGOday
6
13
927
We are on Oncoalert top of the week!! 🤩@VinTarantino @frafanfani @IJGConline @IJGCfellows
11 Sep 2025
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Sept 5-11, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe… Discussing: ✅ EGFR #NSCLC : Amivantamab–Lazertinib vs Osimertinib🫁 Amivantamab–lazertinib boosts 3-year OS to 60% vs 51% in untreated EGFR NSCLC, but watch for higher grade ≥3 toxicities ⚠️ ✅ SCLC: Tarlatamab PD-L1 Inhibitor Tarlatamab with PD-L1 therapy shows manageable toxicity and promising median OS of 25.3 months in extensive-stage #SCLC ✅ COCOON Trial: Skin Toxicity Prevention in EGFR Non Small Cell #LungCancer 🫁 Simple prophylactic dermatologic care cut grade ≥2 skin toxicity from 75% to 42% and improved QoL in patients on amivantamab-lazertinib ✨ ✅A-BRAVE: Adjuvant Avelumab in High-Risk #TNBC Avelumab didn’t improve DFS in high-risk early TNBC but hints at better overall survival, regardless of PD-L1 status 💡 ✅SONIA ctDNA🧬 Analysis: CDK4/6 Timing in Advanced #BreastCancer Pretreatment ctDNA predicts who benefits most from first-line CDK4/6 inhibitors in advanced ER HER2− breast cancer 🧪 ✅ Early Detection of Pancreatic Cancer via cfDNA🩸 Machine learning on cfDNA fragmentomics detects early-stage #PancreaticCancer with >90% accuracy ✅HCC: Epidemiology, Diagnosis & Treatment Hepatocellular carcinoma is rising due to non-viral causes; early detection and immunotherapy improve outcomes but gaps remain 🏥 #LiverCancer ✅Oligometastatic RCC: Radiotherapy☢️ Alone Metastasis-directed radiotherapy delayed systemic therapy nearly 3 years in oligometastatic RCC with minimal toxicity. #KidneyCancer ✅mCRPC: Pembrolizumab Enzalutamide Adding pembrolizumab to enzalutamide didn’t improve survival but increased grade ≥3 toxicities in chemo-naive mCRPC ❌ #ProstateCancer ✅ PORTEC-3: Adjuvant Chemoradiotherapy in High-Risk #EndometrialCancer Chemoradiotherapy boosts 10-year OS to 74% vs 67% with greatest benefit in p53-abnormal tumors 💪 ✅🏥 Stage IV Endometrial Cancer: Surgery & Molecular Profiling Surgery improves survival over chemo alone, and molecular subtype guides prognosis in stage IV endometrial cancer 🔬 ✅ ICIs in Advanced #Sarcoma : IMPRESARC ICIs show modest efficacy overall, but select subtypes like ASPS, chordoma, SMARCA4-deficient, GIST, and NF1-mutated sarcomas get durable responses ✨ @VivekSubbiah @Latinamd @JadChahoud @Jaskirat__SR @LuisLara_M @StephenVLiu @RManochakian @MAWi1dgust @tuttsakhil @AnaVManana @APassaroMD @lungoncdoc @UOzkerim @DrRishabhOnco @M_Torasawa @chulkimMD @RenoHemonc @BZhangMD @BenWestphalen @PathologyPat @yymgcmd @ErikaHamilton9 @YAbdouMD @MamMa_mimumemo @LoiSher @AnisToumeh @ChadTangMD @changjeesuk1 @Sushilberiwal @_ShankarSiva @PavlosMsaouel @Sid423 @drskmishra1984 @urogomez_ @toddscarbrough @gusviani @bhavanaparikh1 @MatteoLoverro @leitaomd
1
9
1,627